Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial tags : Biotech save search
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
Published: 2024-04-23 (Crawled : 12:00) - globenewswire.com
PDSB | $3.2 7.02% 6.56% 990K
|
Health Technology
|
| O: 13.3%
H: 0.0%
C: 0.0%
atile-002 versamune biotech hpv cancer key trial
Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung
Published: 2024-04-22 (Crawled : 11:00) - globenewswire.com
KRYS | News | $162.175 3.13% 3.04% 220K
|
Health Technology
|
| O: -2.94%
H: 1.5%
C: -0.68%
kb707 first lung biotech tumors treatment for trial advanced
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
Published: 2024-04-11 (Crawled : 12:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 1.85%
H: 0.0%
C: 0.0%
biotech fda breast cancer for meeting trial submission
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
Published: 2024-02-13 (Crawled : 12:00) - globenewswire.com
PPBT | $0.485 6.97% 6.52% 82K
|
Manufacturing
|
| O: 4.01%
H: 7.74%
C: -3.82%
nt219 biotech cancer purple trial
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial
Published: 2023-12-21 (Crawled : 13:30) - globenewswire.com
IOBT | $1.435 -0.35% -0.35% 59K
|
|
| O: 2.03%
H: 1.99%
C: -3.31%
first biotech tumor trial
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
Published: 2023-12-14 (Crawled : 12:00) - globenewswire.com
PPBT | $0.485 6.97% 6.52% 82K
|
Manufacturing
|
| O: 4.12%
H: 2.64%
C: -3.3%
biotech cancer pancreatic purple trial
Latest biotech news: fundraises, deals, clinical trials | Nov 24, 2023 – Labiotech.eu
Published: 2023-11-24 (Crawled : 14:30) - spacfeed.com
CLAY 4 | $10.66 3.47% 9.2K
|
| Email alert
Add to watchlist
biotech trials
Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study
Published: 2023-11-20 (Crawled : 00:00) - biospace.com/
EDSA | $4.38 0.22% 2.3K
|
Health Technology
|
| O: -1.99%
H: 14.92%
C: 3.39%
biotech dermatitis results study
IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma
Published: 2023-11-10 (Crawled : 13:00) - globenewswire.com
IOBT | $1.435 -0.35% -0.35% 59K
|
|
| O: -4.36%
H: 4.42%
C: 3.19%
melanoma biotech trial
PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients
Published: 2023-11-09 (Crawled : 15:30) - biospace.com/
PDSB | $3.2 7.02% 6.56% 990K
|
Health Technology
|
| O: 4.94%
H: 4.7%
C: 0.41%
pds0101 biotech cancer trial therapy
PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 Months
Published: 2023-11-09 (Crawled : 13:00) - globenewswire.com
PDSB | $3.2 7.02% 6.56% 990K
|
Health Technology
|
| O: 4.94%
H: 4.7%
C: 0.41%
pds0101 biotech cancer trial therapy show
United States Clinical Trials Support Services Market Analysis Reprot 2023-2028: Pharma & Biotech Companies Invest Heavily, Phase III Trials Anticipated to Showcase Highest Growth Rate
Published: 2023-10-18 (Crawled : 01:00) - prnewswire.com
ICLR | News | $306.16 2.76% 2.68% 860K
|
Health Technology
|
| O: -1.23%
H: 0.3%
C: -3.38%
pharma companies services biotech trials growth market
Early October Sees Torrid Pace of Biotech M&A—Will It Continue?
Published: 2023-10-13 (Crawled : 21:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
biotech
PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer
Published: 2023-10-11 (Crawled : 12:00) - globenewswire.com
PDSB | $3.2 7.02% 6.56% 990K
|
Health Technology
|
| O: -0.42%
H: 2.3%
C: -2.92%
pds0301 drug antibody biotech cancer treat trial response
Biotech Financing, IPO Tide May Be Turning – Signs of a Potential Recovery?
Published: 2023-09-15 (Crawled : 21:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.15%
H: 0.51%
C: -1.54%
biotech potential
Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer
Published: 2023-08-22 (Crawled : 12:20) - biospace.com/
NBIO | $0.0898 15.32% 190K
|
|
| O: 2.29%
H: 12.0%
C: 10.08%
biotech cancer trials
PDS Biotech Announces Data from IMMUNOCERV Phase 2 Trial Investigating PDS0101 and Chemoradiotherapy in Cervical Cancer to be Featured in Oral Presentation at the ASTRO 2023 Annual Meeting
Published: 2023-08-16 (Crawled : 12:00) - globenewswire.com
PDSB | $3.2 7.02% 6.56% 990K
|
Health Technology
|
| O: 7.79%
H: 0.0%
C: 0.0%
pds0101 immunocerv biotech presentation cancer meeting trial
PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 Trial
Published: 2023-08-14 (Crawled : 11:00) - globenewswire.com
PDSB | $3.2 7.02% 6.56% 990K
|
Health Technology
|
| O: 7.87%
H: 7.8%
C: 6.6%
atile-003 fda biotech trial submission
IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer Center
Published: 2023-07-28 (Crawled : 12:00) - globenewswire.com
IOBT | $1.435 -0.35% -0.35% 59K
|
|
| O: 3.13%
H: 0.0%
C: -6.06%
california biotech cancer trial
Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of KB407 for the Treatment of Cystic Fibrosis
Published: 2023-07-03 (Crawled : 11:00) - globenewswire.com
KRYS | News | $162.175 3.13% 3.04% 220K
|
Health Technology
|
| O: -1.81%
H: 2.07%
C: 1.41%
kb407 biotech treatment fibrosis trial
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.